Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Carboplatin

A second-generation platinum chemotherapy drug, developed at the Institute of Cancer Research in Sutton, south London, and licensed in the UK in 1986: it became a standard treatment for ovarian cancer. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards and other impurities.

Did you know?It was chosen from about 300 platinum compounds made in search of a successor to cisplatin: in early trials it proved just as effective, but much less toxic for patients.

CarboplatinGo to the active ingredient →
CarboplatinActive ingredientCarboplatinCat. No. P-C042-001CAS 41575-94-4

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.